MAPT and supranuclear palsy, progressive, 1: Still, though to a lesser extent compared to PSP, this same CpG has shown concordant direction of effect in the FTLD2m dataset (FTLD vs controls, delta-beta = −7.9%, nominal p-value = 0.003), and in all its individual subtype comparisons (FTLD-Tau MAPT mutants vs controls, FTLD-TDP C9orf72 mutants and GRN mutants vs controls, Table 1).